Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.75 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.75 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.75 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13201846 | 0.93 | PIK3CA (0.87) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1821760 | 0.91 | PIK3CA (0.84) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1820669 | 0.90 | PIK3CA (0.82) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1822064 | 0.89 | PIK3CA (0.80) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL2470746 | 0.88 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL2960907 | 0.86 | PIK3CA (0.81) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1821956 | 0.86 | PIK3CA (0.80) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1820153 | 0.86 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1821854 | 0.86 | PIK3CA (1.00) | PIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL14748414 | 0.85 | PIK3CA (0.82) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575940-B1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2011-10-05 | — | — | EP | claimed |
| EP-2316831-B1 | 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | NOVARTIS AG (CH) | 2013-03-06 | — | — | EP | disclosed |
| EP-1575940-B1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2011-10-05 | — | — | EP | disclosed |
| EP-2316831-A1 | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | Novartis AG (CH) | 2011-05-04 | — | — | EP | disclosed |
| US-7423148-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | CHIRON CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423148-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | CHIRON CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423148-B2 | Small molecule PI 3-kinase inhibitors and methods of their use | CHIRON CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |